Compare DexCom, Inc. (DXCM) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? DexCom, Inc. trades at $78.49 (market cap $28.06B), while Vanguard Dividend Appreciation Index Fund ETF trades at $239.07. The key difference: Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | VIG | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | — |
52-Week High | $89.53 | $239.03 |
52-Week Low | $54.84 | $204.09 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
VIG trades at $237.66 with a slight 0.15% daily gain, showing technical bullish momentum with strong moving average support. The ETF maintains focus on dividend growth stocks with consistent performance. Recent news highlights VIG as a core holding for long-term wealth building, with comparisons to peers like SCHD and DGRO emphasizing its dividend appreciation strategy.
VIG offers exposure to companies with strong dividend growth histories, positioned for steady income generation. Key risks include interest rate sensitivity and market volatility affecting dividend stocks. Analyst sentiment remains positive for dividend-focused strategies in current market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
